All In Biotech

Investigational drug · Phase 3

ezetimibe FDC

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

18

Any phase or sponsor naming "ezetimibe FDC"

First trial start

2024

May 16, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ezetimibe FDC", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lipidemia
  • Coronary Artery Disease
  • Plaque, Atherosclerotic
  • Type 2 Diabetes (T2DM)
  • Metabolic Syndrome (MetS)

Approved drugs for the same conditions: Type 2 diabetes · Coronary artery disease and heart attack · Cardiovascular and metabolic · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "ezetimibe FDC" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Lipidemia

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.